Quantitative study of salivary secretion in Parkinson's disease
Identifieur interne : 001B52 ( PascalFrancis/Corpus ); précédent : 001B51; suivant : 001B53Quantitative study of salivary secretion in Parkinson's disease
Auteurs : Omar R. Tumilasci ; Juan E. Belforte ; Federico E. Micheli ; Eduardo E. Benarroch ; Jorge H. PazoSource :
- Movement disorders [ 0885-3185 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
Abstract
We examined basal and reflex salivary flow rate and composition in 46 patients with Parkinson's disease (PD), both in off and on conditions, compared to 13 age-matched controls without underlying disease or treatment affecting autonomic function. Whole saliva was collected 12 hours after withdrawal of dopaminergic drugs and at the peak of levodopa-induced motor improvement. Twenty-three of the 46 PD patients had received domperidone a week before the study. Basal salivary flow rate was significantly lower in PD patients in the off state compared to controls (P < 0.005). Levodopa increased salivary flow rate (P < 0.05) both in the domperidone-pretreated and untreated groups. Citric acid stimulated salivary flow rate in both the off and on states in PD patients. This effect was higher in the domperidone-pretreated patients. Salivary concentration of sodium, chloride, and amylase was higher in PD patients than in controls and was not affected by levodopa or domperidone treatment. Levodopa stimulates both basal and reflex salivary flow rate in PD. The mechanism appears to be central, as the effect is not blocked by domperidone. Domperidone may have a peripheral effect that potentiates reflex salivary secretion. Salivary composition is abnormal in PD and is not affected by levodopa treatment.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 06-0289032 INIST |
---|---|
ET : | Quantitative study of salivary secretion in Parkinson's disease |
AU : | TUMILASCI (Omar R.); BELFORTE (Juan E.); MICHELI (Federico E.); BENARROCH (Eduardo E.); PAZO (Jorge H.) |
AF : | Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires/Buenos Aires/Argentine (1 aut., 3 aut.); Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires/Buenos Aires/Argentine (2 aut., 5 aut.); Department of Neurology, Mayo Clinic/Rochester, Minnesota/Etats-Unis (4 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 5; Pp. 660-667; Bibl. 56 ref. |
LA : | Anglais |
EA : | We examined basal and reflex salivary flow rate and composition in 46 patients with Parkinson's disease (PD), both in off and on conditions, compared to 13 age-matched controls without underlying disease or treatment affecting autonomic function. Whole saliva was collected 12 hours after withdrawal of dopaminergic drugs and at the peak of levodopa-induced motor improvement. Twenty-three of the 46 PD patients had received domperidone a week before the study. Basal salivary flow rate was significantly lower in PD patients in the off state compared to controls (P < 0.005). Levodopa increased salivary flow rate (P < 0.05) both in the domperidone-pretreated and untreated groups. Citric acid stimulated salivary flow rate in both the off and on states in PD patients. This effect was higher in the domperidone-pretreated patients. Salivary concentration of sodium, chloride, and amylase was higher in PD patients than in controls and was not affected by levodopa or domperidone treatment. Levodopa stimulates both basal and reflex salivary flow rate in PD. The mechanism appears to be central, as the effect is not blocked by domperidone. Domperidone may have a peripheral effect that potentiates reflex salivary secretion. Salivary composition is abnormal in PD and is not affected by levodopa treatment. |
CC : | 002B17; 002B17G; 002B17A03 |
FD : | Système nerveux pathologie; Parkinson maladie; Lévodopa; Dompéridone |
FG : | Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie |
ED : | Nervous system diseases; Parkinson disease; Levodopa; Domperidone |
EG : | Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease |
SD : | Sistema nervioso patología; Parkinson enfermedad; Levodopa; Domperidona |
LO : | INIST-20953.354000142568210100 |
ID : | 06-0289032 |
Links to Exploration step
Pascal:06-0289032Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Quantitative study of salivary secretion in Parkinson's disease</title>
<author><name sortKey="Tumilasci, Omar R" sort="Tumilasci, Omar R" uniqKey="Tumilasci O" first="Omar R." last="Tumilasci">Omar R. Tumilasci</name>
<affiliation><inist:fA14 i1="01"><s1>Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Belforte, Juan E" sort="Belforte, Juan E" uniqKey="Belforte J" first="Juan E." last="Belforte">Juan E. Belforte</name>
<affiliation><inist:fA14 i1="02"><s1>Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Micheli, Federico E" sort="Micheli, Federico E" uniqKey="Micheli F" first="Federico E." last="Micheli">Federico E. Micheli</name>
<affiliation><inist:fA14 i1="01"><s1>Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benarroch, Eduardo E" sort="Benarroch, Eduardo E" uniqKey="Benarroch E" first="Eduardo E." last="Benarroch">Eduardo E. Benarroch</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pazo, Jorge H" sort="Pazo, Jorge H" uniqKey="Pazo J" first="Jorge H." last="Pazo">Jorge H. Pazo</name>
<affiliation><inist:fA14 i1="02"><s1>Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0289032</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0289032 INIST</idno>
<idno type="RBID">Pascal:06-0289032</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001B52</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Quantitative study of salivary secretion in Parkinson's disease</title>
<author><name sortKey="Tumilasci, Omar R" sort="Tumilasci, Omar R" uniqKey="Tumilasci O" first="Omar R." last="Tumilasci">Omar R. Tumilasci</name>
<affiliation><inist:fA14 i1="01"><s1>Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Belforte, Juan E" sort="Belforte, Juan E" uniqKey="Belforte J" first="Juan E." last="Belforte">Juan E. Belforte</name>
<affiliation><inist:fA14 i1="02"><s1>Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Micheli, Federico E" sort="Micheli, Federico E" uniqKey="Micheli F" first="Federico E." last="Micheli">Federico E. Micheli</name>
<affiliation><inist:fA14 i1="01"><s1>Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Benarroch, Eduardo E" sort="Benarroch, Eduardo E" uniqKey="Benarroch E" first="Eduardo E." last="Benarroch">Eduardo E. Benarroch</name>
<affiliation><inist:fA14 i1="03"><s1>Department of Neurology, Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pazo, Jorge H" sort="Pazo, Jorge H" uniqKey="Pazo J" first="Jorge H." last="Pazo">Jorge H. Pazo</name>
<affiliation><inist:fA14 i1="02"><s1>Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Domperidone</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Dompéridone</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We examined basal and reflex salivary flow rate and composition in 46 patients with Parkinson's disease (PD), both in off and on conditions, compared to 13 age-matched controls without underlying disease or treatment affecting autonomic function. Whole saliva was collected 12 hours after withdrawal of dopaminergic drugs and at the peak of levodopa-induced motor improvement. Twenty-three of the 46 PD patients had received domperidone a week before the study. Basal salivary flow rate was significantly lower in PD patients in the off state compared to controls (P < 0.005). Levodopa increased salivary flow rate (P < 0.05) both in the domperidone-pretreated and untreated groups. Citric acid stimulated salivary flow rate in both the off and on states in PD patients. This effect was higher in the domperidone-pretreated patients. Salivary concentration of sodium, chloride, and amylase was higher in PD patients than in controls and was not affected by levodopa or domperidone treatment. Levodopa stimulates both basal and reflex salivary flow rate in PD. The mechanism appears to be central, as the effect is not blocked by domperidone. Domperidone may have a peripheral effect that potentiates reflex salivary secretion. Salivary composition is abnormal in PD and is not affected by levodopa treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>21</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Quantitative study of salivary secretion in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>TUMILASCI (Omar R.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BELFORTE (Juan E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MICHELI (Federico E.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>BENARROCH (Eduardo E.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>PAZO (Jorge H.)</s1>
</fA11>
<fA14 i1="01"><s1>Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>2 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Mayo Clinic</s1>
<s2>Rochester, Minnesota</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>660-667</s1>
</fA20>
<fA21><s1>2006</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000142568210100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2006 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>56 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>06-0289032</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We examined basal and reflex salivary flow rate and composition in 46 patients with Parkinson's disease (PD), both in off and on conditions, compared to 13 age-matched controls without underlying disease or treatment affecting autonomic function. Whole saliva was collected 12 hours after withdrawal of dopaminergic drugs and at the peak of levodopa-induced motor improvement. Twenty-three of the 46 PD patients had received domperidone a week before the study. Basal salivary flow rate was significantly lower in PD patients in the off state compared to controls (P < 0.005). Levodopa increased salivary flow rate (P < 0.05) both in the domperidone-pretreated and untreated groups. Citric acid stimulated salivary flow rate in both the off and on states in PD patients. This effect was higher in the domperidone-pretreated patients. Salivary concentration of sodium, chloride, and amylase was higher in PD patients than in controls and was not affected by levodopa or domperidone treatment. Levodopa stimulates both basal and reflex salivary flow rate in PD. The mechanism appears to be central, as the effect is not blocked by domperidone. Domperidone may have a peripheral effect that potentiates reflex salivary secretion. Salivary composition is abnormal in PD and is not affected by levodopa treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B17A03</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dompéridone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Domperidone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Domperidona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>184</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 06-0289032 INIST</NO>
<ET>Quantitative study of salivary secretion in Parkinson's disease</ET>
<AU>TUMILASCI (Omar R.); BELFORTE (Juan E.); MICHELI (Federico E.); BENARROCH (Eduardo E.); PAZO (Jorge H.)</AU>
<AF>Programa de Parkinson y Movimientos Anormales, Instituto de Neurociencias del Hospital de Clínicas, Universidad de Buenos Aires/Buenos Aires/Argentine (1 aut., 3 aut.); Departamento de Fisiología, Laboratorio de Neurofisiología, Facultad de Medicina, Universidad de Buenos Aires/Buenos Aires/Argentine (2 aut., 5 aut.); Department of Neurology, Mayo Clinic/Rochester, Minnesota/Etats-Unis (4 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2006; Vol. 21; No. 5; Pp. 660-667; Bibl. 56 ref.</SO>
<LA>Anglais</LA>
<EA>We examined basal and reflex salivary flow rate and composition in 46 patients with Parkinson's disease (PD), both in off and on conditions, compared to 13 age-matched controls without underlying disease or treatment affecting autonomic function. Whole saliva was collected 12 hours after withdrawal of dopaminergic drugs and at the peak of levodopa-induced motor improvement. Twenty-three of the 46 PD patients had received domperidone a week before the study. Basal salivary flow rate was significantly lower in PD patients in the off state compared to controls (P < 0.005). Levodopa increased salivary flow rate (P < 0.05) both in the domperidone-pretreated and untreated groups. Citric acid stimulated salivary flow rate in both the off and on states in PD patients. This effect was higher in the domperidone-pretreated patients. Salivary concentration of sodium, chloride, and amylase was higher in PD patients than in controls and was not affected by levodopa or domperidone treatment. Levodopa stimulates both basal and reflex salivary flow rate in PD. The mechanism appears to be central, as the effect is not blocked by domperidone. Domperidone may have a peripheral effect that potentiates reflex salivary secretion. Salivary composition is abnormal in PD and is not affected by levodopa treatment.</EA>
<CC>002B17; 002B17G; 002B17A03</CC>
<FD>Système nerveux pathologie; Parkinson maladie; Lévodopa; Dompéridone</FD>
<FG>Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Système nerveux central pathologie</FG>
<ED>Nervous system diseases; Parkinson disease; Levodopa; Domperidone</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease</EG>
<SD>Sistema nervioso patología; Parkinson enfermedad; Levodopa; Domperidona</SD>
<LO>INIST-20953.354000142568210100</LO>
<ID>06-0289032</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B52 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001B52 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:06-0289032 |texte= Quantitative study of salivary secretion in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |